Supplementary Method 1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
crossref（2024）
摘要
Supplementary Method. Inclusion and exclusion criteria of the dose-escalation, dose-expansion, and clinical expansion part I of this phase 1 study.
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要